Skip to main content
main-content
Erschienen in: Die Chirurgie 1/2022

07.12.2021 | Sarkome | Leitthema

Medikamentöse Therapie retroperitonealer Weichteilsarkome

verfasst von: Johanna Falkenhorst, Rainer Hamacher, Prof. Dr. Sebastian Bauer

Erschienen in: Die Chirurgie | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Retroperitoneale Weichgewebssarkome stellen höchste Anforderungen an interdisziplinäre Behandlungsteams. Die sarkomspezifische Erfahrung von Chirurgen hat den höchsten Einfluss auf die Heilungschancen. Allerdings sterben zu viele Patienten trotz optimaler Lokaltherapien. Der Stellenwert der Chemotherapie ist lediglich bei Patienten mit hoch malignen Knochensarkomen oder Rhabdomyosarkomen unstrittig. Für Weichteilsarkome des Erwachsenenalters, insbesondere Liposarkome und Leiomyosarkome, ist die Evidenzlage sehr unbefriedigend. Der Übersichtsartikel diskutiert die komplexe Datenlage und kontroversen Aspekte, die für eine Entscheidungsfindung interdisziplinärer Behandlungsteams relevant sind.
Literatur
1.
Zurück zum Zitat Abendroth A, Bauer S (2013) Adjuvant chemotherapy for soft tissue sarcoma? a clear no—well—yes-ish. Dtsch Med Wochenschr 138:2107–2110 CrossRef Abendroth A, Bauer S (2013) Adjuvant chemotherapy for soft tissue sarcoma? a clear no—well—yes-ish. Dtsch Med Wochenschr 138:2107–2110 CrossRef
2.
Zurück zum Zitat Ardoino I, Miceli R, Berselli M et al (2010) Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. Cancer 116:2429–2436 PubMed Ardoino I, Miceli R, Berselli M et al (2010) Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. Cancer 116:2429–2436 PubMed
3.
Zurück zum Zitat Arndt CA, Crist WM (1999) Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 341:342–352 CrossRef Arndt CA, Crist WM (1999) Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 341:342–352 CrossRef
4.
Zurück zum Zitat Bauer S, Demetri GD, Halilovic E et al (2021) Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies. Br J Cancer 125:687–698 CrossRef Bauer S, Demetri GD, Halilovic E et al (2021) Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies. Br J Cancer 125:687–698 CrossRef
5.
Zurück zum Zitat Ben-Ami E, Barysauskas CM, Solomon S et al (2017) Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study. Cancer 123:3285–3290 CrossRef Ben-Ami E, Barysauskas CM, Solomon S et al (2017) Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study. Cancer 123:3285–3290 CrossRef
6.
Zurück zum Zitat Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790 CrossRef Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790 CrossRef
7.
Zurück zum Zitat Bissler JJ, Kingswood JC, Radzikowska E et al (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381:817–824 CrossRef Bissler JJ, Kingswood JC, Radzikowska E et al (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381:817–824 CrossRef
8.
Zurück zum Zitat Cocco E, Scaltriti M, Drilon A (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731–747 CrossRef Cocco E, Scaltriti M, Drilon A (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731–747 CrossRef
9.
Zurück zum Zitat D’ambrosio L, Touati N, Blay JY et al (2020) Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European organization for research and treatment of cancer soft tissue and bone sarcoma group. Cancer 126:2637–2647 CrossRef D’ambrosio L, Touati N, Blay JY et al (2020) Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European organization for research and treatment of cancer soft tissue and bone sarcoma group. Cancer 126:2637–2647 CrossRef
10.
Zurück zum Zitat D’Angelo SP, Mahoney MR, Van Tine BA et al (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416–426 CrossRef D’Angelo SP, Mahoney MR, Van Tine BA et al (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416–426 CrossRef
11.
Zurück zum Zitat Dickson MA, Schwartz GK, Keohan ML et al (2016) Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial. JAMA Oncol 2:937–940 CrossRef Dickson MA, Schwartz GK, Keohan ML et al (2016) Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial. JAMA Oncol 2:937–940 CrossRef
12.
Zurück zum Zitat Dieckmann N, Schildhaus HU, Bauer S (2021) Tropomyosin receptor kinases in sarcomas—of joy and despair. Curr Opin Oncol 33:336–344 CrossRef Dieckmann N, Schildhaus HU, Bauer S (2021) Tropomyosin receptor kinases in sarcomas—of joy and despair. Curr Opin Oncol 33:336–344 CrossRef
13.
Zurück zum Zitat Eilber F, Giuliano A, Eckardt J et al (1987) Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 5:21–26 CrossRef Eilber F, Giuliano A, Eckardt J et al (1987) Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 5:21–26 CrossRef
14.
Zurück zum Zitat Frustaci S, Berretta M, Comandone A et al (2006) Adjuvant treatment of high-risk adult soft tissue sarcomas: a survey by the Italian sarcoma group. Tumori 92:92–97 CrossRef Frustaci S, Berretta M, Comandone A et al (2006) Adjuvant treatment of high-risk adult soft tissue sarcomas: a survey by the Italian sarcoma group. Tumori 92:92–97 CrossRef
15.
Zurück zum Zitat Frustaci S, Gherlinzoni F, De Paoli A et al (2001) Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 19:1238–1247 CrossRef Frustaci S, Gherlinzoni F, De Paoli A et al (2001) Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 19:1238–1247 CrossRef
16.
Zurück zum Zitat George S, Miao D, Demetri GD et al (2017) Loss of PTEN is associated with resistance to anti-PD‑1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity 46:197–204 CrossRef George S, Miao D, Demetri GD et al (2017) Loss of PTEN is associated with resistance to anti-PD‑1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity 46:197–204 CrossRef
17.
Zurück zum Zitat Gronchi A, Ferrari S, Quagliuolo V et al (2017) Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 18:812–822 CrossRef Gronchi A, Ferrari S, Quagliuolo V et al (2017) Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 18:812–822 CrossRef
19.
Zurück zum Zitat Henze J, Bauer S (2013) Liposarcomas. Hematol Oncol Clin North Am 27:939–955 CrossRef Henze J, Bauer S (2013) Liposarcomas. Hematol Oncol Clin North Am 27:939–955 CrossRef
20.
Zurück zum Zitat Italiano A, Delva F, Mathoulin-Pelissier S et al (2010) Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French sarcoma group database. Ann Oncol 21:2436–2441 CrossRef Italiano A, Delva F, Mathoulin-Pelissier S et al (2010) Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French sarcoma group database. Ann Oncol 21:2436–2441 CrossRef
22.
Zurück zum Zitat Nesbit ME Jr., Gehan EA, Burgert EO Jr. et al (1990) Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the first intergroup study. J Clin Oncol 8:1664–1674 CrossRef Nesbit ME Jr., Gehan EA, Burgert EO Jr. et al (1990) Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the first intergroup study. J Clin Oncol 8:1664–1674 CrossRef
23.
Zurück zum Zitat Paoluzzi L, Cacavio A, Ghesani M et al (2016) Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res 6:24 CrossRef Paoluzzi L, Cacavio A, Ghesani M et al (2016) Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res 6:24 CrossRef
24.
Zurück zum Zitat Pasquali S, Colombo C, Pizzamiglio S et al (2018) High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. Eur J Cancer 93:28–36 CrossRef Pasquali S, Colombo C, Pizzamiglio S et al (2018) High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. Eur J Cancer 93:28–36 CrossRef
25.
Zurück zum Zitat Pasquali S, Pizzamiglio S, Touati N et al (2019) The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer 109:51–60 CrossRef Pasquali S, Pizzamiglio S, Touati N et al (2019) The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer 109:51–60 CrossRef
26.
Zurück zum Zitat Paulussen M, Craft AW, Lewis I et al (2008) Results of the EICESS-92 study: two randomized trials of Ewing’s sarcoma treatment—cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 26:4385–4393 CrossRef Paulussen M, Craft AW, Lewis I et al (2008) Results of the EICESS-92 study: two randomized trials of Ewing’s sarcoma treatment—cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 26:4385–4393 CrossRef
27.
Zurück zum Zitat Pervaiz N, Colterjohn N, Farrokhyar F et al (2008) A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113:573–581 CrossRef Pervaiz N, Colterjohn N, Farrokhyar F et al (2008) A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113:573–581 CrossRef
28.
Zurück zum Zitat Tawbi HA, Burgess M, Bolejack V et al (2017) Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18:1493–1501 CrossRef Tawbi HA, Burgess M, Bolejack V et al (2017) Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18:1493–1501 CrossRef
29.
Zurück zum Zitat Toulmonde M, Bonvalot S, Ray-Coquard I et al (2014) Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French sarcoma group. Ann Oncol 25:730–734 CrossRef Toulmonde M, Bonvalot S, Ray-Coquard I et al (2014) Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French sarcoma group. Ann Oncol 25:730–734 CrossRef
30.
Zurück zum Zitat Vanhersecke L, Brunet M, Guégan J‑P et al (2021) Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer 2:794–802 CrossRef Vanhersecke L, Brunet M, Guégan J‑P et al (2021) Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer 2:794–802 CrossRef
31.
Zurück zum Zitat Villano AM, Zeymo A, Chan KS et al (2020) Identifying the minimum volume threshold for retroperitoneal soft tissue sarcoma resection: merging national data with consensus expert opinion. J Am Coll Surg 230:151–160.e2 CrossRef Villano AM, Zeymo A, Chan KS et al (2020) Identifying the minimum volume threshold for retroperitoneal soft tissue sarcoma resection: merging national data with consensus expert opinion. J Am Coll Surg 230:151–160.e2 CrossRef
32.
Zurück zum Zitat Woll PJ, Reichardt P, Le Cesne A et al (2012) Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 13:1045–1054 CrossRef Woll PJ, Reichardt P, Le Cesne A et al (2012) Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 13:1045–1054 CrossRef
Metadaten
Titel
Medikamentöse Therapie retroperitonealer Weichteilsarkome
verfasst von
Johanna Falkenhorst
Rainer Hamacher
Prof. Dr. Sebastian Bauer
Publikationsdatum
07.12.2021
Verlag
Springer Medizin
Erschienen in
Die Chirurgie / Ausgabe 1/2022
Print ISSN: 2731-6971
Elektronische ISSN: 2731-698X
DOI
https://doi.org/10.1007/s00104-021-01539-x